Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era

Patrick Ingiliz; Malte H Wehmeyer; Christoph Boesecke; Julian Schulze Zur Wiesch; Knud Schewe; Thomas Lutz; Axel Baumgarten; Karl-Georg Simon; Dietrich Hueppe; Juergen K Rockstroh; Stefan Mauss; Stefan Christensen; NEAT study group; GECCO Consortium

doi:10.1093/cid/ciz949

Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era

Standard

Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era. / Ingiliz, Patrick; Wehmeyer, Malte H; Boesecke, Christoph; Schulze Zur Wiesch, Julian; Schewe, Knud; Lutz, Thomas; Baumgarten, Axel; Simon, Karl-Georg; Hueppe, Dietrich; Rockstroh, Juergen K; Mauss, Stefan; Christensen, Stefan; NEAT study group; GECCO Consortium.

In: CLIN INFECT DIS, Vol. 71, No. 5, 22.08.2020, p. 1248-1254.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ingiliz, P, Wehmeyer, MH, Boesecke, C, Schulze Zur Wiesch, J, Schewe, K, Lutz, T, Baumgarten, A, Simon, K-G, Hueppe, D, Rockstroh, JK, Mauss, S, Christensen, S, NEAT study group & GECCO Consortium 2020, 'Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era', CLIN INFECT DIS, vol. 71, no. 5, pp. 1248-1254. https://doi.org/10.1093/cid/ciz949

APA

Ingiliz, P., Wehmeyer, M. H., Boesecke, C., Schulze Zur Wiesch, J., Schewe, K., Lutz, T., Baumgarten, A., Simon, K-G., Hueppe, D., Rockstroh, J. K., Mauss, S., Christensen, S., NEAT study group, & GECCO Consortium (2020). Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era. CLIN INFECT DIS, 71(5), 1248-1254. https://doi.org/10.1093/cid/ciz949

Vancouver

Ingiliz P, Wehmeyer MH, Boesecke C, Schulze Zur Wiesch J, Schewe K, Lutz T et al. Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era. CLIN INFECT DIS. 2020 Aug 22;71(5):1248-1254. https://doi.org/10.1093/cid/ciz949

Bibtex

@article{1345d597d6d444c78ff7888daa247dde,

title = "Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era",

abstract = "BACKGROUND: Micro-elimination of the hepatitis C virus (HCV) includes treatment in populations at risk of ongoing HCV transmission, such as men who have sex with men (MSM) or people who inject drugs (PWID). We analyzed the HCV reinfection incidence rates of participants in the German hepatitis C cohort (GECCO) and compared our data to previous findings from the interferon era.METHODS: Patients with HCV reinfections in the multi-centric GECCO cohort were compared to patients in whom no reinfection occurred. The HCV reinfection incidence rate in MSM was also compared to the incidence rate in the interferon era (using data from the European Acquired Immunodeficiency Syndrome Treatment Network [NEAT]).RESULTS: Between January 2014 and April 2018, 48 HCV reinfections occurred in 2298 individuals (2%), with 2346 cured HCV episodes. The median time to reinfection was 500 days (range 16-1160) and the overall HCV reinfection incidence rate was 1.89 per 100 person-years (py; 95% confidence interval [CI], 1.41-2.48). In a multivariate analysis, the transmission risk in MSM was the only independent risk factor of HCV reinfection (odds ratio, 39.3; 95% CI, 4.57-334.40; P = .001). The incidence rate in MSM was 9.02 (95% CI, 6.48-12.26) per 100 py, compared to 1.14 per 100 py in PWID (95% CI, .56-2.09). The incidence rate for a first HCV reinfection in MSM was similar in the direct-acting antiviral era, compared to the interferon era, with a hazard ratio of 1.05 (95% CI, .64-1.74; P = .831).CONCLUSIONS: HCV reinfection remains a frequent finding among MSM in Germany. In addition to behavioral interventions, early HCV treatment and retreatment should be implemented for this subgroup to prevent HCV transmission.",

author = "Patrick Ingiliz and Wehmeyer, {Malte H} and Christoph Boesecke and {Schulze Zur Wiesch}, Julian and Knud Schewe and Thomas Lutz and Axel Baumgarten and Karl-Georg Simon and Dietrich Hueppe and Rockstroh, {Juergen K} and Stefan Mauss and Stefan Christensen and {NEAT study group} and {GECCO Consortium}",

note = "{\textcopyright} The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.",

year = "2020",

month = aug,

day = "22",

doi = "10.1093/cid/ciz949",

language = "English",

volume = "71",

pages = "1248--1254",

journal = "CLIN INFECT DIS",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

RIS

TY - JOUR

T1 - Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era

AU - Ingiliz, Patrick

AU - Wehmeyer, Malte H

AU - Boesecke, Christoph

AU - Schulze Zur Wiesch, Julian

AU - Schewe, Knud

AU - Lutz, Thomas

AU - Baumgarten, Axel

AU - Simon, Karl-Georg

AU - Hueppe, Dietrich

AU - Rockstroh, Juergen K

AU - Mauss, Stefan

AU - Christensen, Stefan

AU - NEAT study group

AU - GECCO Consortium

PY - 2020/8/22

Y1 - 2020/8/22

N2 - BACKGROUND: Micro-elimination of the hepatitis C virus (HCV) includes treatment in populations at risk of ongoing HCV transmission, such as men who have sex with men (MSM) or people who inject drugs (PWID). We analyzed the HCV reinfection incidence rates of participants in the German hepatitis C cohort (GECCO) and compared our data to previous findings from the interferon era.METHODS: Patients with HCV reinfections in the multi-centric GECCO cohort were compared to patients in whom no reinfection occurred. The HCV reinfection incidence rate in MSM was also compared to the incidence rate in the interferon era (using data from the European Acquired Immunodeficiency Syndrome Treatment Network [NEAT]).RESULTS: Between January 2014 and April 2018, 48 HCV reinfections occurred in 2298 individuals (2%), with 2346 cured HCV episodes. The median time to reinfection was 500 days (range 16-1160) and the overall HCV reinfection incidence rate was 1.89 per 100 person-years (py; 95% confidence interval [CI], 1.41-2.48). In a multivariate analysis, the transmission risk in MSM was the only independent risk factor of HCV reinfection (odds ratio, 39.3; 95% CI, 4.57-334.40; P = .001). The incidence rate in MSM was 9.02 (95% CI, 6.48-12.26) per 100 py, compared to 1.14 per 100 py in PWID (95% CI, .56-2.09). The incidence rate for a first HCV reinfection in MSM was similar in the direct-acting antiviral era, compared to the interferon era, with a hazard ratio of 1.05 (95% CI, .64-1.74; P = .831).CONCLUSIONS: HCV reinfection remains a frequent finding among MSM in Germany. In addition to behavioral interventions, early HCV treatment and retreatment should be implemented for this subgroup to prevent HCV transmission.

AB - BACKGROUND: Micro-elimination of the hepatitis C virus (HCV) includes treatment in populations at risk of ongoing HCV transmission, such as men who have sex with men (MSM) or people who inject drugs (PWID). We analyzed the HCV reinfection incidence rates of participants in the German hepatitis C cohort (GECCO) and compared our data to previous findings from the interferon era.METHODS: Patients with HCV reinfections in the multi-centric GECCO cohort were compared to patients in whom no reinfection occurred. The HCV reinfection incidence rate in MSM was also compared to the incidence rate in the interferon era (using data from the European Acquired Immunodeficiency Syndrome Treatment Network [NEAT]).RESULTS: Between January 2014 and April 2018, 48 HCV reinfections occurred in 2298 individuals (2%), with 2346 cured HCV episodes. The median time to reinfection was 500 days (range 16-1160) and the overall HCV reinfection incidence rate was 1.89 per 100 person-years (py; 95% confidence interval [CI], 1.41-2.48). In a multivariate analysis, the transmission risk in MSM was the only independent risk factor of HCV reinfection (odds ratio, 39.3; 95% CI, 4.57-334.40; P = .001). The incidence rate in MSM was 9.02 (95% CI, 6.48-12.26) per 100 py, compared to 1.14 per 100 py in PWID (95% CI, .56-2.09). The incidence rate for a first HCV reinfection in MSM was similar in the direct-acting antiviral era, compared to the interferon era, with a hazard ratio of 1.05 (95% CI, .64-1.74; P = .831).CONCLUSIONS: HCV reinfection remains a frequent finding among MSM in Germany. In addition to behavioral interventions, early HCV treatment and retreatment should be implemented for this subgroup to prevent HCV transmission.

U2 - 10.1093/cid/ciz949

DO - 10.1093/cid/ciz949

M3 - SCORING: Journal article

C2 - 31562816

VL - 71

SP - 1248

EP - 1254

JO - CLIN INFECT DIS

JF - CLIN INFECT DIS

SN - 1058-4838

IS - 5

ER -